Description

3α-Paricalcitol is a synthetic analog of calcitriol, the active form of vitamin D, specifically designed for enhanced therapeutic utility. This compound is a critical active pharmaceutical ingredient (API) used in the formulation of medications to treat secondary hyperparathyroidism associated with chronic kidney disease. It is essential for pharmaceutical manufacturers and research institutions developing targeted endocrine therapies. The product is supplied under stringent quality controls to ensure purity and stability for sensitive pharmaceutical applications.

Application

• Pharmaceutical API: Primary use as the active ingredient in prescription medications for managing mineral and bone disorders in patients with chronic kidney disease (CKD).
• Therapeutic Agent for Hyperparathyroidism: Formulated into injectable solutions and oral capsules specifically for treating secondary hyperparathyroidism.
• Biochemical Research: Used as a high-purity reference standard and reagent in metabolic pathway studies, particularly those involving vitamin D receptor (VDR) activation.
• Drug Development: Serves as a key intermediate or target molecule in the R&D of new vitamin D analogs and related endocrine therapies.
• Clinical Diagnostics: May be utilized in the calibration of assays and diagnostic kits designed to measure vitamin D metabolites and related biomarkers.

Basic Information

Product Name	3α-Paricalcitol
CAS No.	216161-87-4
Molecular Formula	C₂₇H₄₄O₃
Molecular Weight	416.64 g/mol
Synonyms	Paricalcitol; 19-Nor-1,25-dihydroxyvitamin D2; 19-Nor-1-alpha,25-dihydroxyvitamin D2; Zemplar (brand name); 1α,25-Dihydroxy-19-norvitamin D₂; (1R,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R,5S)-5-ethyl-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
EINECS	Contact for details

Quality Control

Our 3α-Paricalcitol is manufactured and tested to meet the stringent requirements for pharmaceutical active ingredients. Quality is assured through a comprehensive battery of analytical tests including HPLC for purity and assay, and spectroscopic methods for identification. A Certificate of Analysis (COA) is provided with each batch, detailing compliance with established specifications. Production is aligned with cGMP principles to ensure consistency and reliability for critical therapeutic applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed after each use to prevent degradation from atmospheric moisture. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.